AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24953368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-selecting therapy (TST)
Number of subjects: 120
Study 24953368 — intervention group
Group type: COMPARATOR
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 120
Study 22884437 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality balance games (VRBG)
Number of subjects: 36
Study 22884437 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 36
Study 20495932 — intervention group
Group type: EXPERIMENTAL
Intervention: Including group (inclusion of the fracture level)
Number of subjects: 80
Study 20495932 — intervention group
Group type: COMPARATOR
Intervention: Bridging group (excluding the fracture level)
Number of subjects: 80
Study 18670858 — intervention group
Group type: EXPERIMENTAL
Intervention: Norcholesterol scintigraphy
Number of subjects: 78
Study 18670858 — intervention group
Group type: EXPERIMENTAL
Intervention: CT attenuation value
Number of subjects: 78
Study 18670858 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical-shift MRI suppression index
Number of subjects: 78
Study 15772862 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 12
Study 15772862 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan balancing amino acid drink (placebo)
Number of subjects: 12
Study 12960371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg once a day)
Number of subjects: 32
Study 12960371 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX-4016 (800 mg twice a day)
Number of subjects: 32
Study 12960371 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice a day) with aspirin
Number of subjects: 32
Study 12960371 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice a day) with NCX-4016
Number of subjects: 32
Study 12960371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and NCX-4016
Number of subjects: 32
Study 12960371 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 32
Study 10096935 — intervention group
Group type: EXPERIMENTAL
Intervention: AV junction ablation and DDDR/MS pacing
Number of subjects: 56
Study 10096935 — intervention group
Group type: COMPARATOR
Intervention: DDDR/MS pacing
Number of subjects: 56
Study 10096935 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 56
Study 8694619 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg methylprednisolone in the pump prime (group II)
Number of subjects: 24
Study 8694619 — intervention group
Group type: EXPERIMENTAL
Intervention: No steroid (group I)
Number of subjects: 24
Study 8694619 — intervention group
Group type: COMPARATOR
Intervention: Control (group III)
Number of subjects: 24
Study 1751270 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia with continuous infusion of 0.25% bupivacaine with fentanyl
Number of subjects: 53
Study 1751270 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia with continuous infusion of 0.25% bupivacaine without fentanyl
Number of subjects: 53
Study 1751270 — intervention group
Group type: COMPARATOR
Intervention: Parenteral opioid analgesia
Number of subjects: 53
Study 6153035 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-7 (Cu-7) IUD
Number of subjects: 398
Study 6153035 — intervention group
Group type: COMPARATOR
Intervention: Copper-T (Cu-T) IUD
Number of subjects: 398
Study 30425008 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR) focused on personal goals using Goal Attainment Scaling (GAS)
Number of subjects: 315
Study 30425008 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of recommendations for GAS-related drug-related problems (DRPs)
Number of subjects: 315
Study 29560909 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) treatment, 20 iTBS sessions applied to the left dorsolateral prefrontal cortex (5 daily sessions spread over 4 days)
Number of subjects: 50
Study 29560909 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 50
Study 27333958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aster spathulifolius Maxim extract (700 mg/d of ASE)
Number of subjects: 44
Study 27333958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25234526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg and Celecoxib 400 mg (experimental group)
Number of subjects: 0
Study 25234526 — intervention group
Group type: COMPARATOR
Intervention: Lactose powder 2 g (placebo group)
Number of subjects: 0
Study 21571464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbsan(®) (calcium alginate)
Number of subjects: 40
Study 21571464 — intervention group
Group type: COMPARATOR
Intervention: Beschitin‐F(®) (chitin‐coated gauze)
Number of subjects: 40
Study 19384168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Tac
Number of subjects: 156
Study 19384168 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CsA
Number of subjects: 156
Study 19384168 — intervention group
Group type: COMPARATOR
Intervention: Low dose of CsA
Number of subjects: 156
Study 19384168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with serum creatinine ≤ 1.5 mg/mL
Number of subjects: 156
Study 19384168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute rejection
Number of subjects: 156
Study 17587625 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injection plus therapeutic exercise
Number of subjects: 64
Study 17587625 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs plus therapeutic exercise
Number of subjects: 64
Study 15986724 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Swallowing Therapy (FST)
Number of subjects: 208
Study 12147313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/h intravenous unfractionated heparin (UFH), n=70
Number of subjects: 167
Study 12147313 — intervention group
Group type: COMPARATOR
Intervention: 300 mg oral aspirin, n=97
Number of subjects: 167
Study 11192234 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg b.i.d. for 2 weeks
Number of subjects: 20
Study 12013486 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium mineral water (sodium, chloride and bicarbonate < 0.02 mmol/l)
Number of subjects: 21
Study 12013486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-rich mineral water (sodium 39.3 mmol/l, chloride 6.5 mmol/l, bicarbonate 48.8 mmol/l)
Number of subjects: 21
Study 12013486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride-rich mineral water (sodium 84.5 mmol/l, chloride 63.7 mmol/l, bicarbonate 21.9 mmol/l)
Number of subjects: 21
Study 12013486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium mineral water
Number of subjects: 21
Study 12013486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-rich mineral water
Number of subjects: 21
Study 12013486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride-rich mineral water
Number of subjects: 21
Study 12013486 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 21
Study 1601536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (NG)
Number of subjects: 99
Study 1601536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum plus psychological treatment (NG-PT)
Number of subjects: 99
Study 1601536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum plus psychological treatment and partner support (NG-PT-PS)
Number of subjects: 99
Study 1601536 — intervention group
Group type: COMPARATOR
Intervention: Control (no partner support)
Number of subjects: 99
Study 6440186 — intervention group
Group type: EXPERIMENTAL
Intervention: CR (Contingent Reward)
Number of subjects: 24
Study 6440186 — intervention group
Group type: EXPERIMENTAL
Intervention: IO (Information Only)
Number of subjects: 24
Study 6440186 — intervention group
Group type: EXPERIMENTAL
Intervention: NCR (Noncontingent Reward)
Number of subjects: 24
Study 6440186 — intervention group
Group type: COMPARATOR
Intervention: NR (No Reward)
Number of subjects: 24
Study 6440186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (session 5)
Number of subjects: 24
Study 30095230 — intervention group
Group type: EXPERIMENTAL
Intervention: PASS Plus
Number of subjects: 40
Study 30095230 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 40
Study 30103735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified food
Number of subjects: 0
Study 30103735 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 0
Study 30103735 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Number of subjects: 0
Study 27171733 — intervention group
Group type: COMPARATOR
Intervention: MacIntosh
Number of subjects: 21
Study 27171733 — intervention group
Group type: EXPERIMENTAL
Intervention: KVL
Number of subjects: 21
Study 27171733 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq®
Number of subjects: 21
Study 27171733 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 21
Study 25528834 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) escitalopram
Number of subjects: 0
Study 22710821 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human Cu/Zn superoxide dismutase (rhSOD)
Number of subjects: 302
Study 22710821 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study 20478877 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch alone (alternate SSRI or venlafaxine)
Number of subjects: 334
Study 20478877 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch plus cognitive‐behavioral therapy (CBT)
Number of subjects: 334
Study 20478877 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders by week 12
Number of subjects: 334
Study 20478877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders by week 12
Number of subjects: 334
Study 19085343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/25 mg
Number of subjects: 880
Study 19085343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/12.5 mg
Number of subjects: 880
Study 19085343 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 300 mg monotherapy
Number of subjects: 880
Study 15905733 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 33
Study 12881590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to patients with ocular hypertension.
Number of subjects: 0
Study 12881590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to healthy volunteers.
Number of subjects: 0
Study 10320172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine (0.5% in 80 mL)
Number of subjects: 80
Study 10320172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IM morphine (10 mg in 1 mL) and intraperitoneal lidocaine (0.5% in 80 mL)
Number of subjects: 80
Study 10320172 — intervention group
Group type: COMPARATOR
Intervention: IM morphine (10 mg in 1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Number of subjects: 80
Study 10320172 — intervention group
Group type: COMPARATOR
Intervention: IM isotonic sodium chloride solution (1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Number of subjects: 80
Study 10172702 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone intervention provided to 19 subjects
Number of subjects: 354
Study 10172702 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 subjects who refused intervention)
Number of subjects: 354
Study 1888692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 20 mg of ketanserin
Number of subjects: 37
Study 1888692 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 20 mg of ketanserin
Number of subjects: 37
Study 29480185 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based multidomain intervention for cardiovascular risk management
Number of subjects: 2500
Study 28487911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziyinqingre prescription (Chinese Traditional Medicine), administered twice a day for two weeks
Number of subjects: 84
Study 28487911 — intervention group
Group type: COMPARATOR
Intervention: Montelukast Sodium tablets, 10mg once a day for two weeks (Control)
Number of subjects: 84
Study 24263469 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL Turkish coffee (57 mg caffeine/100 mL)
Number of subjects: 62
Study 24263469 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 62
Study 22640678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sydney Magnoglide and comprehensive fixed appliance therapy
Number of subjects: 34
Study 20604657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment manoeuvre (5 manual inflations of the lungs with positive pressure ventilation of 40 cmH(2)O at the end of surgery)
Number of subjects: 146
Study 20604657 — intervention group
Group type: COMPARATOR
Intervention: Traditional passive deflation of abdominal cavity (Control)
Number of subjects: 146
Study 18339561 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Waddell approach
Number of subjects: 50
Study 18339561 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated anteromedial approach
Number of subjects: 50
Study 18339561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral patellar approach
Number of subjects: 50
Study 15764779 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium dichromate C30 globules, 5 globules administered twice daily at intervals of 12 h
Number of subjects: 50
Study 15764779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12444480 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between size and colour of square blocks (e.g. red = large; yellow = small)
Number of subjects: 0
Study 12444480 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent kinematic conditions (blocks presented in the same location)
Number of subjects: 0
Study 12444480 — intervention group
Group type: COMPARATOR
Intervention: Variable kinematic conditions (blocks presented in different locations)
Number of subjects: 0
Study 10524887 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser resection
Number of subjects: 120
Study 10524887 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatic resection
Number of subjects: 120
Study 7717643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac
Number of subjects: 60
Study 7717643 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesia
Number of subjects: 60
Study 1786194 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ plus PSK
Number of subjects: 103
Study 1786194 — intervention group
Group type: COMPARATOR
Intervention: CQ alone
Number of subjects: 103
Study 6128722 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 54
Study 6128722 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 54
Study 6128722 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 54
Study 29528443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 to 40 Gy of low-energy photons in addition to standard radiochemotherapy
Number of subjects: 15
Study 30083727 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention using telephone‐delivered behavioral interviewing by trained clinical pharmacists, text messaging, pillboxes, and mailed progress reports.
Number of subjects: 4078
Study 30083727 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4078
Study 30083727 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 4078
Study 25838271 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP + TTC
Number of subjects: 48
Study 25838271 — intervention group
Group type: COMPARATOR
Intervention: MIP alone
Number of subjects: 48
Study 24439651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile Extract 100 mg three times a day
Number of subjects: 90
Study 24439651 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (MA) 250 mg three times a day
Number of subjects: 90
Study 22846235 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 36
Study 22846235 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 36
Study 22846235 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol beverage
Number of subjects: 36
Study 19460655 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week e-mail program with individually tailored, small-step goals; personal homepage with tips; educational materials; tracking and simulation tools
Number of subjects: 787
Study 19460655 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week e-mail program
Number of subjects: 787
Study 16612619 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable cement restrictor
Number of subjects: 130
Study 16612619 — intervention group
Group type: COMPARATOR
Intervention: Non-degradable cement restrictor
Number of subjects: 130
Study 16612619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 14520142 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 152
Study 14520142 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 152
Study 10972367 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 10881
Study 10972367 — intervention group
Group type: COMPARATOR
Intervention: Diuretics and beta-blockers
Number of subjects: 10881
Study 8849401 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic women (n = 34)
Number of subjects: 113
Study 8849401 — intervention group
Group type: COMPARATOR
Intervention: Nonatherosclerotic women (n = 79)
Number of subjects: 113
Study 1296494 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiray 300
Number of subjects: 0
Study 1296494 — intervention group
Group type: COMPARATOR
Intervention: Iopamiron 370
Number of subjects: 0
Study 6500777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine teprosilate (1 ampoule i.v.)
Number of subjects: 10
Study 6500777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ampoule i.v.)
Number of subjects: 10
Study 31956931 — intervention group
Group type: EXPERIMENTAL
Intervention: 27G vitrectomy
Number of subjects: 60
Study 31956931 — intervention group
Group type: COMPARATOR
Intervention: 25G vitrectomy
Number of subjects: 60
Study 31324354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 100
Study 31324354 — intervention group
Group type: COMPARATOR
Intervention: Periarticular Infiltration (PAI)
Number of subjects: 100
Study 27995346 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing (stress Intervention Functional IFA)
Number of subjects: 38
Study 27995346 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 38
Study 26070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable EEG pattern at 24 hours
Number of subjects: 277
Study 26070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent pupillary light responses at 48 hours
Number of subjects: 277
Study 26070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent somatosensory evoked potentials at 72 hours
Number of subjects: 277
Study 26070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable EEG patterns at 12 hours, absent or extensor motor response to pain at 72 hours, and higher age
Number of subjects: 277
Study 26070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable EEG patterns at 12 hours
Number of subjects: 277
Study 26070341 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG beyond 24 hours
Number of subjects: 277
Study 23842856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane
Number of subjects: 731
Study 23842856 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT2B15*2
Number of subjects: 731
Study 23842856 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR1 PvuII polymorphism
Number of subjects: 731
Study 21623000 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (TNF)
Number of subjects: 60
Study 21623000 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD methotrexate, sulphasalazine and hydroxychloroquine in combination (COMBO)
Number of subjects: 60
Study 21623000 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (MTX)
Number of subjects: 60
Study 20047115 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus metformin
Number of subjects: 34
Study 20047115 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride plus metformin
Number of subjects: 34
Study 16510745 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab plus interferon beta-1a
Number of subjects: 1171
Study 16510745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (interferon beta-1a alone)
Number of subjects: 1171
Study 14749551 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinograf
Number of subjects: 18
Study 14749551 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 18
Study 11236120 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 62
Study 11236120 — intervention group
Group type: COMPARATOR
Intervention: Single dose systemic methotrexate (50 mg/m2)
Number of subjects: 62
Study 11236120 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment success rates
Number of subjects: 62
Study 11236120 — intervention group
Group type: COMPARATOR
Intervention: Physical functioning scores
Number of subjects: 62
Study 11236120 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral tubal patency rates
Number of subjects: 62
Study 9605644 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) (lenograstim; 5 microg/kg body weight per day subcutaneously)
Number of subjects: 149
Study 9605644 — intervention group
Group type: COMPARATOR
Intervention: Control (no G‐CSF)
Number of subjects: 149
Study 9605644 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF)
Number of subjects: 149